The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid

The enhancing effect of other proteins
  • Oscar D. Ratnoff
    Reprint requests: Dr. Oscar D. Ratnoff, University Hospitals of Cleveland, Cleveland, Ohio 44106.
    From the Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, U.S.A.

    From the University Hospitals of Cleveland, Cleveland, Ohio, U.S.A.
    Search for articles by this author
  • Hidehiko Saito
    From the Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, U.S.A.

    From the University Hospitals of Cleveland, Cleveland, Ohio, U.S.A.
    Search for articles by this author
  • Author Footnotes
    1 Dr. Ratnoff is a Career Investigator of the American Heart Association.
      This paper is only available as a PDF. To read, Please Download here.


      Ellagic acid (4,4′,5,5′,6,6′-hexahydroxydiphenic acid 2,6,2′,6′-dilactone) can substitute for negatively charged surfaces as a stimulus to reactions of the intrinsic pathway. Incubation of solutions of 4 × 10−6M ellagic acid with purified HF (factor XII) induced clot-promoting and amidolytic activity. Clot-promoting activity tested on a substrate of HF-deficient plasma evolved much more rapidly than amidolytic activity. Clot-promoting activity generated in mixtures of HF and ellagic acid alone, but amidolytic activity was observed only if additional proteins such as albumin were also present. Treatment of purified HF with DFP or filtration of HF through columns of SBTI bound to agarose did not prevent its subsequent activation by ellagic acid. Solutions of SBTI, at high concentration, partly inhibited the generation of amidolytic activity, whereas popcorn inhibitor and a crude lgG fraction of anti-HF inhibited the amidolytic activity that had been generated in a mixture of HF and ellagic acid. Generation of clotting and amidolytic properties was accompanied by scission of HF within an internal disulfide loop and by cleavage of HF into fragments with approximate MWs of 50,000 and 30,000; cleavage was completely blocked by popcorn inhibitor and partially blocked by high concentrations of SBTI. These experiments demonstrate that ellagic acid can activate HF in a manner analogous to negatively charged solids such as glass or kaolin.


      Hageman factor, or factor XII ((HF)), plasma thromboplastin antecedent, or factor XI ((PTA)), diisopropylfluorophosphate ((DFP)), soybean trypsin inhibitor ((SBTI)), H-d-prolyl-l-phenylalanyl-l-arginine p-nitroanilide dihydrochloride ((HPPAN)), p-nitroaniline ((p-NA)), high-molecular-weight ((HMW)), sodium dodecyl sulfate-polyacrylamide gel electrophoresis ((SDS-PAGE)), molecular weight ((MW))
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ratnoff OD
        • Saito H
        Surface-mediated reactions.
        Curr Top Hematol. 1979; 2: 1
        • Ratnoff OD
        • Saito H
        Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent.
        in: Proc Natl Acad Sci USA. 76. 1979: 958
        • Wiggins RC
        • Cochrane CG
        The autoactivation of rabbit Hageman factor.
        J Exp Med. 1979; 150: 1122
        • Heimark RL
        • Kurachi K
        • Fujikawa K
        • Davie EW
        Surface activation of blood coagulation, fibrinolysis and kinin formation.
        Nature. 1980; 286: 456
        • Miller G
        • Silverberg M
        • Kaplan AP
        Autoactivatability of human Hageman factor (factor XII).
        Biochem Biophys Res Commun. 1980; 92: 803
        • Silverberg M
        • Dunn JT
        • Garen L
        • Kaplan AP
        Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate.
        J Biol Chem. 1980; 255: 7281
        • Ratnoff OD
        • Crum JD
        Activation of Hageman factor by solutions of ellagic acid.
        J Lab Clin Med. 1964; 63: 359
        • Ratnoff OD
        • Saito H
        Amidolytic properties of single-chain activated Hageman factor.
        in: Proc Natl Acad Sci USA. 76. 1979: 1461
        • Zimmerman TS
        • Ratnoff OD
        • Powell AE
        Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand's disease.
        J Clin Invest. 1971; 50: 244
        • Zimmerman TS
        • Ratnoff OD
        • Littell AS
        Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor VIII).
        J Clin Invest. 1971; 50: 255
        • Ratnoff OD
        The relative amidolytic activity of Hageman factor (factor XII) and its fragments. The effect of high-molecular-weight kininogen and kaolin.
        J Lab Clin Med. 1980; 96: 267
        • Weber K
        • Osborn M
        The reliability of molecular weight determination by dodecyl sulfatepolyacrylamide gel electrophoresis.
        J Biol Chem. 1969; 244: 4406
        • McConahey PJ
        • Dixon FJ
        A method of trace iodination of proteins for immunologic studies.
        Int Arch Allergy Appl Immunol. 1966; 29: 185
        • Saito H
        Purification of high molecular weight kininogen and the role of this agent in blood coagulation.
        J Clin Invest. 1977; 60: 584
        • Scott CF
        • Liu CY
        • Colman RW
        Human plasma prekallikrein: a rapid high-yield method for purification.
        Eur J Biochem. 1979; 100: 77
        • Goldsmith Jr, GH
        Contact-activated fibrinolysis: role of surface concentration and high-molecular-Weight kininogen.
        J Lab Clin Med. 1980; 96: 222
        • Saito H
        • Ratnoff OD
        • Donaldson VH
        • Haney J
        • Pensky J
        Inhibitors of the adsorption of Hageman factor (factor XII) to glass by normal human plasma.
        J Lab Clin Med. 1974; 84: 62
        • Svendsen L
        • Blombäck B
        • Blombäck M
        • Olsson PI
        Synthetic chromogenic substrates for determination of trypsin, thrombin and thrombin-like enzymes.
        Thromb Res. 1971; 1: 267
        • Ratnoff OD
        • Davie EW
        The purification of activated Hageman factor (activated factor XII).
        Biochemistry. 1962; 1: 967
        • Hojima J
        • Pierce JV
        • Pisano JJ
        Hageman factor fragment inhibitor in corn seeds: purification and characterization.
        Thromb Res. 1980; 20: 149
        • Ratnoff OD
        • Moneme V
        Inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments by popcorn inhibitor.
        in: Proc Soc Exp Biol Med. 166. 1981: 297
        • Revak SD
        • Cochrane CG
        • Griffin JH
        The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
        J Clin Invest. 1977; 59: 1167
        • Greengard JS
        • Griffin JH
        Does soluble ellagic acid activate factor XII (Hageman factor)?.
        Circulation. 1980; 62 (abst.): III, 56
        • Ratnoff OD
        • Saito H
        Evidence that Fitzgerald factor counteracts inhibition by kaolin or ellagic acid of the amidolytic properties of a plasma kallikrein.
        Blood. 1976; 47: 243
        • Griffin JH
        • Cochrane CG
        Recent advances in the understanding of contact activation reactions.
        in: Semin Thromb Haemost. 5. 1979: 254
        • Bock PE
        • Srinivasan KR
        • Shore JD
        Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid-metal ion complexes are the activating species.
        Biochemistry. 1981; 20: 7258